Mesalazine Teva (Mesalazine)

Mesalazine releases 5‑aminosalicylic acid in the gastrointestinal tract where it blocks cyclooxygenase and lipoxygenase enzymes, lowering prostaglandin and leukotriene production. It also modulates cytokines such as interleukin‑1 and TNF‑α, resulting in reduced mucosal inflammation.

The dosage of Mesalazine Teva is individualized. A qualified prescriber determines the appropriate strength, frequency and duration based on the patient’s condition, severity of disease and response to therapy. No generic dosing regimen is provided here.

Safety data for mesalazine during pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient. Use only if clearly needed and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mesalazine belongs to the 5‑ASA class, offering a topical anti‑inflammatory effect with minimal systemic exposure. Compared with sulfasalazine, it lacks the sulfapyridine moiety, reducing certain side effects. Biologic agents provide systemic immunomodulation but are typically reserved for moderate‑to‑severe disease when 5‑ASA therapy is insufficient.

Store Mesalazine Teva at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Mesalazine Teva is taken orally as a tablet. It can be swallowed with a glass of water, with or without food, as directed by the prescribing clinician. Patients should follow any specific instructions regarding timing relative to meals.

The most serious adverse events include severe allergic reactions (rash, swelling, breathing difficulty), hepatotoxicity (elevated liver enzymes or jaundice), and kidney impairment such as interstitial nephritis. Patients should seek immediate medical attention if any of these symptoms appear.

Mesalazine should be avoided in individuals with known hypersensitivity to mesalazine or other 5‑ASA compounds. It is also contraindicated in patients with severe renal or hepatic impairment, and caution is advised for those with a history of blood dyscrasias or severe allergic reactions.